Handelsavisen
prelaunch
Companies Healthcare JANL.PK
JA
JANL.PK OTC Diversified Pharmaceuticals

Janel Group LLC

$58,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
3,1 %
ROE
21,9 %
Net margin
2,7 %
Debt / equity
0,72
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-11-09
Ex-dividend
TR 1Y
About

JANL.PK operates in the Pharmaceuticals & Medical Research industry, focusing on the development, production, and distribution of pharmaceutical products.

Business. JANL.PK is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.

Classification99 %
SectorHealth Care
Industry groupDiversified Pharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsFY 2026 earnings (expected)2026-11-09 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
21,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning JANL.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to JANL.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsFY 2026 earnings (expected)2026-11-09 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    JANL.PK is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Pharmaceuticals
    AI synthesis
    GENERATED

    JANL.PK has a liquidity position that is below the industry median, with a current ratio of 0.74, indicating that the company's current assets are less than its current liabilities. The company's cash and equivalents amount to $10.96 million, while its long-term debt is $18.56 million, resulting in a negative net cash position. The liquidity_fpt metric shows a moderate liquidity risk, with the company's operating cash flow of $43.07 million partially offsetting its debt obligations.

    In terms of profitability, JANL.PK's return on equity (ROE) is 21.92%, which is significantly higher than the industry median, indicating strong returns for shareholders. However, the return on assets (ROA) is 3.31%, which is lower than the industry median, suggesting that the company is not efficiently utilizing its assets to generate profits. The gross profit margin is 31.33%, and the operating margin is 3.09%, both of which are below the industry median, indicating that the company is facing cost pressures.

    JANL.PK's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's revenue is entirely derived from its pharmaceutical operations, and there is no information available on geographic revenue distribution. This lack of diversification increases the company's exposure to market-specific risks.

    The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The operating income has remained relatively flat, and the net income has slightly declined. The capital expenditure is negative, indicating that the company is not investing in new assets, which may limit its long-term growth potential.

    The risk assessment for JANL.PK indicates a medium liquidity risk and a low dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations. The dilution potential is low, as the number of shares outstanding is the same for both basic and diluted shares, indicating no imminent threat of share dilution.

    Recent events related to JANL.PK include the latest financial filing, which provides an updated view of the company's financial position. There are no recent earnings call transcripts or other material events disclosed in the available data.

    Key takeaways
    • JANL.PK has a strong return on equity (21.92%) but a weak return on assets (3.31%), indicating inefficiencies in asset utilization.
    • The company's liquidity position is weak, with a current ratio of 0.74 and a negative net cash position.
    • Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • Growth is limited, with flat operating income and a negative capital expenditure.
    • The company has a low dilution risk, with no difference between basic and diluted shares outstanding.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $58,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $25.8M
    Net cash
    -$7.6M
    Current ratio
    0.7
    Debt / equity
    0.7
    ROA
    3.3%
    ROE
    21.9%
    Cash conversion
    761.0%
    CapEx / revenue
    -0.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Pharmaceuticals1 042,4B node revenueMCK 38,7%COR 30,8%CAH 21,4%DB 3,4%REGN 1,4%BIIB 0,9%ZTS 0,9%GRFS 0,8%Other 1,7%
    Source: company disclosures · own-taxonomy revenue-covered setJANL 0,0% · rank #16 of 40

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs JANL · multiples and returns
    MC
    MCK
    Mckesson Corp
    $827,14
    102,6B USD
    P/E
    21,2x
    vs self
    Div yield
    0,4 %
    vs self
    ROE
    -219,2 %
    vs self
    CO
    COR
    Cencora Inc
    $308,37
    60,2B USD
    P/E
    36,4x
    vs self
    Div yield
    0,8 %
    vs self
    ROE
    45,7 %
    vs self
    CA
    CAH
    Cardinal Health Inc
    $235,60
    57,0B USD
    P/E
    36,7x
    vs self
    Div yield
    0,9 %
    vs self
    ROE
    -55,9 %
    vs self
    DB
    DB
    DB.V
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    RE
    REGN
    REGENERON PHARMACEUTICALS, INC.
    $757,99
    81,0B USD
    P/E
    15,5x
    vs self
    Div yield
    vs self
    ROE
    14,2 %
    vs self
    BI
    BIIB
    BIOGEN INC.
    $201,74
    29,6B USD
    P/E
    21,3x
    vs self
    Div yield
    vs self
    ROE
    7,5 %
    vs self
    ZT
    ZTS
    Zoetis Inc
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    GR
    GRFS
    Grifols SA
    $7,86
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin3,1 %Above median
    Net Margin2,7 %Above median
    ROE21,9 %Above P75
    Capex / Rev-0,3 %Above median
    D/E0,72Bottom quartile
    Cash Conv7,61Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • JANL.PK Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    JANL.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 58.3%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 61.3%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 18.2%Derived (calculated)
    • Current ratio (FY 2025-12-31): 0.74xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 6.24xDerived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 185.8%Derived (calculated)
    • Total assets (annual): USD 176.12MSEC XBRL filing
    • Long-term debt (annual): USD 9.12MSEC XBRL filing
    • Current assets (annual): USD 94.91MSEC XBRL filing
    • Shares outstanding (annual): 1.19MSEC XBRL filing
    • Current liabilities (annual): USD 127.95MSEC XBRL filing
    • Cash & equivalents (annual): USD 6.72MSEC XBRL filing
    • Total liabilities (annual): USD 147.22MSEC XBRL filing
    • Shareholders' equity (annual): USD 23.59MSEC XBRL filing
    • Operating income (YoY) (2025-09-30 vs 2024-09-30): 71.2%Derived (calculated)
    • Gross profit (YoY) (2025-09-30 vs 2024-09-30): 11.3%Derived (calculated)
    • Gross margin (FY 2025-09-30): 31.3%Derived (calculated)
    • Net margin (FY 2025-09-30): 2.7%Derived (calculated)
    • EPS (basic) (YoY) (2025-09-30 vs 2024-09-30): 2,131.6%Derived (calculated)
    • Revenue (YoY) (2025-09-30 vs 2024-09-30): 13.2%Derived (calculated)
    • Net income (YoY) (2025-09-30 vs 2024-09-30): 926.7%Derived (calculated)
    • Operating cash flow (YoY) (2025-09-30 vs 2024-09-30): 530.4%Derived (calculated)
    • Cost of revenue (YoY) (2025-09-30 vs 2024-09-30): 14.1%Derived (calculated)
    • EPS (diluted) (YoY) (2025-09-30 vs 2024-09-30): 2,216.7%Derived (calculated)
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-11-09EVENTUpcomingFY 2026 earnings (expected) estimated date
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage